Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
about
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicityA role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.New assays for monitoring haemophilia treatment.Thrombin generation testing in haemophilia comprehensive care centres.Management of bleeding disorders: basic science.Past, present and future of hemophilia: a narrative review.Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.New predictive approaches for ITI treatment.Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.Current and emerging factor VIII replacement products for hemophilia A.Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.Thrombin Generation Assays (TGAs).Methodological shortcomings in assessment of factor VIII concentrate inhibition.Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.
P2860
Q26866323-81C56D22-D289-4861-9191-94E368BBAA58Q35176160-C9CBCF01-4CC9-4561-977C-36E69797E29EQ37124978-9A58D35F-ABA4-4467-AE6F-CC6730ADF5BBQ37176506-F7D75923-F002-4FD2-A166-0C54D5C2441FQ37589662-96F92EC6-FD4E-4590-982B-A4D5EA7B0DC2Q38005178-D60C20D5-DD73-4071-9034-44061A456EDBQ38007018-308CD174-14C1-446B-AAF1-383422B2B8FEQ38224295-AC7AFCE5-8682-49F3-A174-1EFE49844A67Q38224297-7BBEFEFD-5213-4304-A6EF-3FCE58CF250AQ40375335-9A43FEFA-A5BD-44D5-8CD5-CEBF172DD2E4Q41809588-81D2E444-D988-48E9-9F9F-9F8F05636A46Q42375640-6BDE61A2-79F8-4F47-AF8E-B3C88BD9B5E5Q42408107-98989EBE-1D7A-4400-8BCB-98BDB72055C0Q45870722-90BD8800-316E-43D4-8BD7-0C93909189F6Q45871345-EE6717D0-6ABC-4A8C-AD7C-072829A03362Q45871996-9C4DA2BD-5885-4B1F-828B-60AD1E63ED2E
P2860
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Impact of different inhibitor ...... trates on thrombin generation.
@en
Impact of different inhibitor ...... trates on thrombin generation.
@nl
type
label
Impact of different inhibitor ...... trates on thrombin generation.
@en
Impact of different inhibitor ...... trates on thrombin generation.
@nl
prefLabel
Impact of different inhibitor ...... trates on thrombin generation.
@en
Impact of different inhibitor ...... trates on thrombin generation.
@nl
P2093
P2860
P1433
P1476
Impact of different inhibitor ...... trates on thrombin generation.
@en
P2093
Astermark J
Berntorp E
Franchini M
Salvagno GL
P2860
P356
10.1111/J.1365-2516.2006.01400.X
P577
2007-01-01T00:00:00Z